C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Moderate Buy" from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $11.60.

Several research firms recently commented on CCCC. Stephens began coverage on C4 Therapeutics in a research report on Monday, November 18th. They issued an "equal weight" rating and a $4.00 price target for the company. Wells Fargo & Company upgraded C4 Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $8.00 to $12.00 in a research report on Thursday, December 19th. Finally, UBS Group upgraded C4 Therapeutics to a "hold" rating in a research report on Friday, February 14th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Sei Investments Co. purchased a new position in shares of C4 Therapeutics during the fourth quarter valued at approximately $45,000. Point72 DIFC Ltd purchased a new position in shares of C4 Therapeutics during the third quarter valued at approximately $51,000. Kazazian Asset Management LLC purchased a new position in shares of C4 Therapeutics during the fourth quarter valued at approximately $51,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of C4 Therapeutics during the fourth quarter valued at approximately $54,000. Finally, Cynosure Group LLC purchased a new position in shares of C4 Therapeutics during the third quarter valued at approximately $57,000. Hedge funds and other institutional investors own 78.81% of the company's stock.

C4 Therapeutics Stock Up 0.7 %

CCCC traded up $0.02 on Wednesday, hitting $3.01. The company had a trading volume of 868,136 shares, compared to its average volume of 1,824,953. The company has a market cap of $212.48 million, a PE ratio of -1.77 and a beta of 2.95. C4 Therapeutics has a 12-month low of $2.79 and a 12-month high of $11.88. The business's fifty day simple moving average is $3.67 and its 200 day simple moving average is $4.93.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.